Nanaware Padma P, Ramteke Manoj P, Somavarapu Arun K, Venkatraman Prasanna
Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India.
Proteins. 2014 Jul;82(7):1283-300. doi: 10.1002/prot.24494. Epub 2014 Jan 15.
Gankyrin, a non-ATPase component of the proteasome and a chaperone of proteasome assembly, is also an oncoprotein. Gankyrin regulates a variety of oncogenic signaling pathways in cancer cells and accelerates degradation of tumor suppressor proteins p53 and Rb. Therefore gankyrin may be a unique hub integrating signaling networks with the degradation pathway. To identify new interactions that may be crucial in consolidating its role as an oncogenic hub, crystal structure of gankyrin-proteasome ATPase complex was used to predict novel interacting partners. EEVD, a four amino acid linear sequence seems a hot spot site at this interface. By searching for EEVD in exposed regions of human proteins in PDB database, we predicted 34 novel interactions. Eight proteins were tested and seven of them were found to interact with gankyrin. Affinity of four interactions is high enough for endogenous detection. Others require gankyrin overexpression in HEK 293 cells or occur endogenously in breast cancer cell line- MDA-MB-435, reflecting lower affinity or presence of a deregulated network. Mutagenesis and peptide inhibition confirm that EEVD is the common hot spot site at these interfaces and therefore a potential polypharmacological drug target. In MDA-MB-231 cells in which the endogenous CLIC1 is silenced, trans-expression of Wt protein (CLIC1_EEVD) and not the hot spot site mutant (CLIC1_AAVA) resulted in significant rescue of the migratory potential. Our approach can be extended to identify novel functionally relevant protein-protein interactions, in expansion of oncogenic networks and in identifying potential therapeutic targets.
泛素连接酶E3结合蛋白(Gankyrin)是蛋白酶体的一种非ATP酶成分,也是蛋白酶体组装的伴侣蛋白,同时还是一种癌蛋白。Gankyrin调节癌细胞中的多种致癌信号通路,并加速肿瘤抑制蛋白p53和Rb的降解。因此,Gankyrin可能是一个将信号网络与降解途径整合在一起的独特枢纽。为了确定在巩固其作为致癌枢纽的作用中可能至关重要的新相互作用,利用Gankyrin - 蛋白酶体ATP酶复合物的晶体结构来预测新的相互作用伙伴。EEVD,一个四氨基酸线性序列,似乎是这个界面上的一个热点位点。通过在蛋白质数据银行(PDB)数据库中搜索人类蛋白质暴露区域中的EEVD,我们预测了34种新的相互作用。测试了8种蛋白质,发现其中7种与Gankyrin相互作用。四种相互作用的亲和力高到足以进行内源性检测。其他相互作用需要在人胚肾293(HEK 293)细胞中过表达Gankyrin,或者在乳腺癌细胞系MDA - MB - 435中内源性发生,这反映了较低的亲和力或失调网络的存在。诱变和肽抑制证实EEVD是这些界面上的共同热点位点,因此是一个潜在的多靶点药物靶点。在沉默内源性氯离子细胞内通道蛋白1(CLIC1)的MDA - MB - 231细胞中,野生型蛋白(CLIC1_EEVD)而非热点位点突变体(CLIC1_AAVA)的转表达导致迁移潜能的显著恢复。我们的方法可以扩展到识别新的功能相关的蛋白质 - 蛋白质相互作用,扩展致癌网络并识别潜在的治疗靶点。